전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,092 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleRochePhase 1

TACE combined with sintilimab and bevacizumab (TACE combined with sintilimab and bevacizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase1#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleSecond Affiliated Hospital of G…Phase 2

TACE combined with sorafenib and tislelizumab (TACE combined with sorafenib and tislelizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase2#monoclonal-antibody#Second
Trials 1Status Active
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

atezolizumab (Tecentriq, TACE-HACI, plus atezolizumab-bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Sun
Trials 1Status Recruiting
CGTLimited DatastaleShanghai GeneChem Co., Ltd.Phase 2

TAI-GPC3-CART cells (TAI-GPC3-CART cells)

Carcinoma, Hepatocellular · Carcinoma, Hepatocellular

#CarcinomaHepatocellular#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 1

TGFBR-2 KO CD70 CAR NK (TGFBR-2 KO CD70 CAR NK)

Clear Cell Carcinoma; Phase 1 · Clear Cell Carcinoma

#ClearCellCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 1

TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells (TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells)

Breast Cancer · TROP2

#TROP2#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 1

TGFβR-KO CAR-EGFR T Cells (TGFβR-KO CAR-EGFR T Cells)

Solid Tumor, Adult; EGFR Overexpression · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
AntibodyLimited DatastaleTJ Biopharma Co., Ltd.Phase 2

pembrolizumab (Keytruda, TJ107 +Pembrolizumab)

Triple-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#Antibody#Phase2#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Active
CGTLimited DatastalesuhaichuanPreclinical

TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy (TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy)

Advanced Solid Tumor; Neoplasms · Advanced Solid Tumor

#AdvancedSolidTumor#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleEdiGene Inc.Phase 2

TRAC and Power3 (SPPL3, TRAC and Power3, TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T))

Non Hodgkin's Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBellicum Pharmaceuticals, Inc.Phase 1

TROP2-CAR-NK Cells (TROP2-CAR-NK Cells)

Colorectal Cancer; Minimal Residual Disease · TROP2

#TROP2#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleWest China HospitalPhase 2

Tagitanlimab (Tagitanlimab)

Resectable Head and Neck Squamous Cell Carcinoma · Resectable Head and Neck Squamous Cell C

#ResectableHeadandNeckSquamousCel#Antibody#Phase2#monoclonal-antibody#West
Trials 1Status Recruiting
CGTLimited Datastale920th Hospital of Joint Logisti…Phase 1

Target CD7 CAR-T cells (Target CD7 CAR-T cells)

T-cell Acute Lymphoblastic Leukemia; T-lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 1

Targeting CD276 CAR T cells (Targeting CD276 CAR T cells)

Osteosarcoma; Neuroblastoma · Osteosarcoma

#Osteosarcoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Preclinical

Targeting CD276 autologous chimeric antigen receptor T cells (Targeting CD276 autologous chimeric antigen receptor T cells)

CAR; Solid Tumor · CAR

#CAR#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Preclinical

Therapeutic 4SCAR19 cells (Therapeutic 4SCAR19 cells)

B-cell Malignancies · B-cell Malignancies

#B-cellMalignancies#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
CGTLimited DatastaleWuhan Bio-Raid Biotechnology Co…Phase 1

Third generation CAR-T cells (Third generation CAR-T cells)

B Cell Lymphoma; Acute Lymphoblastic Leukemia · B Cell Lymphoma

#BCellLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleWuhan Bio-Raid Biotechnology Co…Phase 1

Third-generation anti-CD123 CAR-T cells (Third-generation anti-CD123 CAR-T cells)

CD123+ Acute Myeloid Leukemia · CD123+ Acute Myeloid Leukemia

#CD123+AcuteMyeloidLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleFundamenta Therapeutics, Ltd.Phase 1

ThisCART19 cells (ThisCART19 cells)

B Cell Malignancy · B Cell Malignancy

#BCellMalignancy#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleFundamenta Therapeutics, Ltd.Phase 1

ThisCART22 cells (ThisCART22 cells)

B-cell Malignancy · B-cell Malignancy

#B-cellMalignancy#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active

49 / 55 pages

← PreviousNext →